Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-05-31T07:28:29.165Z Has data issue: false hasContentIssue false
  • English
  • Français

Eye movements and neurocognitive function in treatment resistant schizophrenia: a pilot study

Published online by Cambridge University Press:  13 June 2014

Annette Thampi ,
Clarke Campbell ,
Mary Clarke ,
Suzanne Barrett  and
David J King
Annette Thampi
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University, Belfast, and Holywell Hospital, Antrim, Northern Ireland (now: The Early Psychosis Prevention and Intervention Centre (EPPIC), Parkville, Victoria, Australia)
Clarke Campbell
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University, and Holywell Hospital, Antrim (now: Daisy Hill Hospital, Newry, Northern Ireland)
Mary Clarke
Affiliation:
Holywell Hospital, Antrim, Northern Ireland
Suzanne Barrett
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University, Belfast, Northern Ireland
David J King
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University, Belfast, Northern Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: It is increasingly important to develop predictors of treatment response and outcome in schizophrenia. Neuropsychological impairments, particularly those reflecting frontal lobe function, appear to predict poor outcome. Eye movement abnormalities probably also reflect frontal lobe deficits. We wished to see if these two aspects of schizophrenia were correlated and whether they could distinguish a treatment resistant from a treatment responsive group.

Methods: Ten treatment resistant schizophrenic patients were compared with ten treatment responsive patients on three eye movement paradigms (reflexive saccades, antisaccades and smooth pursuit), clinical psychopathology (BPRS, SANS and CGI) and a neuropsychological test battery designed to detect frontal lobe dysfunction. Ten aged-matched controls also carried out the eye movement tasks.

Results: Both treatment responsive (p = 0.038) and treatment resistant (p = 0.007) patients differed significantly from controls on the antisaccade task. The treatment resistant group had a higher error rate than the treatment responsive group, but the difference was not statistically significant. Similar poor neuropsychological test performance was found in both groups.

Conclusions: To demonstrate the biological differences characteristic of treatment resistance, larger sample sizes and wider differences in outcome between the two groups are necessary.

Keywords

AntisaccadesSmooth pursuitNeuropsychologyTreatment resistanceSchizophrenia
Type
Original Papers
Information
Irish Journal of Psychological Medicine , Volume 20 , Issue 1 , March 2003 , pp. 6 - 10
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.May, PRA, Dencker, SJ, Hubbard, JW, Midha, KK, Liberman, RP. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker, SJ, Kulhanek, F, editors. Treatment Resistance in Schizophrenia. Braunschweig/Wiesbaden: Viewag Verlag, 1998: 22–33.Google Scholar
2.Johnstone, EC, Sandler, R. Treatment resistance in schizophrenia. Br Med J 1996; 312: 325–326.CrossRefGoogle ScholarPubMed
3.Bondolfi, G, Baumann, P, Dufour, H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. European Neuropsychopharmacology 1996; 6(suppl 2):21–25.CrossRefGoogle ScholarPubMed
4.Kane, J, Honigfield, G, Binger, J, Meltzer, H. Clozapine for the treatment resistant schizophrenic: A double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–796.CrossRefGoogle ScholarPubMed
5.Breier, A, Buchanan, R, Kirkpatrick, Bet al.Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. A double blind comparison with chlorpromazine. Am J Psychiatry 1994; 151: 20–25.Google Scholar
6.Brenner, HD, Dencker, SJ, Goldstein, MJet al.Defining treatment refractoriness in schizophrenia. Schizophrenia Bull 1990; 16: 551–556.CrossRefGoogle ScholarPubMed
7.Lieberman, JA, Jody, D, Geisler, S. Treatment outcome of first episode schizophrenia. Psychopharmacology Bull 1989; 25: 92–96.Google ScholarPubMed
8.Lieberman, JA, Jody, D, Geisler, Set al.Time course and biological predictors of treatment response in first episode schizophrenia. Arch Gen Psychiatry 1993; 50: 369–376.CrossRefGoogle ScholarPubMed
9.King, DJ. Drug Treatment of the negative symptoms of schizophrenia. European Neuropsychopharmacology 1998; 8: 33–42.CrossRefGoogle ScholarPubMed
10.Wolkin, A, Sanfiiipo, M, Wolf, A, Angrist, B, Brodie, JD, Rotrosen, J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49: 959–965.CrossRefGoogle ScholarPubMed
11 . Merriam, AE, Kay, SR, Opler, LA, Kushner, SF, Van Praag, H. Neurological signs and the positive negative dimension in schizophrenia. Biological Psychiatry 1990; 28:181–192.CrossRefGoogle ScholarPubMed
12.Pantelis, C, Barnes, TRE, Nelson, HEet al.Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997; 120: 1823–1843.CrossRefGoogle ScholarPubMed
13.Diefendorf, AR, Dodge, R. An experimental study of the ocular reactions of the insane from photographic records. Brain 1908; 31: 451–489.CrossRefGoogle Scholar
14.Holzman, PS, Levy, DL, Proctor, LR. Smooth pursuit eye movements, attention and schizophrenia. Arch Gen Psychiatry 1976; 33: 1415–1420.CrossRefGoogle ScholarPubMed
15.Lacono, WG. Eye movement abnormalities in schizophrenic and affective disorders. In: Johnston, CW, Pirozollo, FJ, editors. Neuropsychology of eye movements. Hillsdale, NJ: LEA, 1988:115–145.Google Scholar
16.Sereno, AB, Holzman, PS. Antisaccades and smooth pursuit eye movements in schizophrenia. Biological Psychiatry 1995; 37: 394–401.CrossRefGoogle ScholarPubMed
17.Fukushima, J, Fukushima, K, Miyasaka, K, Yamashita, I. Voluntary control of saccadic eye movements in patients with frontal cortical lesions and Parkinsonian patients in comparison with that in schizophrenics. Biological Psychiatry 1994; 36: 21–30.CrossRefGoogle ScholarPubMed
18.Fukushima, J, Morita, N, Fukushima, K, Chiba, T, Tanaka, S, Yamashita, I. Voluntary control of saccadic eye movements in patients with schizophrenic and affective disorders. J Psychiatric Research 1990; 24: 9–24.CrossRefGoogle ScholarPubMed
19.Fukushima, J, Fukushima, K, Moriata, N, Yamashita, I. The control of voluntary saccadic eye movements in schizophrenic patients. Biological Psychiatry 1990; 28: 943–948.CrossRefGoogle ScholarPubMed
20.Crawford, TJ, Haeger, B, Kennard, C, Reveley, MA, Henderson, L. Saccadic abnormalities in psychotic patients. I. Neuroleptic-free psychotic patients. Psychological Medicine 1995; 25: 461–471.CrossRefGoogle ScholarPubMed
21.Crawford, TJ, Haeger, B, Kennard, C, Reveley, MA, Henderson, L. Saccadic abnormalities in psychotic patients II. The role of neuroleptic treatment. Psychological Medicine 1995; 25: 473–483.CrossRefGoogle ScholarPubMed
22.Guitton, D, Buchtel, HA, Douglas, RM. Frontal lobe lesions in man causing difficulties in suppressing reflexive glances and in generating goal directed saccades. Experimental Brain Research 1985; 58: 455–472.CrossRefGoogle ScholarPubMed
23.Crawford, TJ, Puri, BK, Nijran, KS, Jones, B, Kennard, C, Lewis, SW. Abnormal saccadic distractibility in patients with schizophrenia: a99mTc-HMPAO SPET study. Psychological Medicine 1996; 26: 265–277.CrossRefGoogle ScholarPubMed
24.Pierrot-Deseilligny, C, Rivaud, S, Gaymard, B, Agid, Y. Cortical control of reflexive visually-guided saccades. Brain 1991; 114:1473–1485.CrossRefGoogle ScholarPubMed
25.Wykes, T, Sturt, E, Katz, R. The prediction of rehabilitation success after three years. The use of social symptom and cognitive variables. Br J Psychiatry 1990; 157:865–870.CrossRefGoogle ScholarPubMed
26.Green, MRWhat are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321–330.Google ScholarPubMed
27.Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962; 10:799–812.CrossRefGoogle Scholar
28.Andreason, NC. Negative symptoms in schizophrenia - definition and reliability. Archives of General Psychiatry 1982; 39: 784–788.CrossRefGoogle Scholar
29.Simpson, GM, Angus, JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scand 1970; Supple.212: 11–19.Google Scholar
30.Barnes, TRE. A rating scale for drug induced akathisia. Br J Psychiatry 1989; 154: 672–676.CrossRefGoogle ScholarPubMed
31. Abnormal Involuntary Movement Scale, 1976. (AIMS: National Institute of Mental Health, 1976).Google Scholar
32.Griffiths, AN, Marshall, RW, Richens, . Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. Br J Clin Pharmacology 1984; 18: 73S–82S.CrossRefGoogle ScholarPubMed
33.Marshall, RW, Griffiths, AN, Richens, A. A microcomputer system to assess CNS depression from the analysis of the dynamics of saccadic eye movements. Br J Clin Pharmacology 1985; 20: 304–305.Google Scholar
34.Green, JF, King, DJ, Trimble, KM. Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacology 2000; 14: 30–36.CrossRefGoogle ScholarPubMed
35.Wechsler, D. Manual for Wechsler Adult Intelligence Scale, revised. Psychological Cooperation 1981, New York.Google Scholar
36.Wilson, BA, Cockburn, JM, Baddeley, AD, 1985. The Rivermead Behavioural Memory Test. Thames Valley Test Co: 34–36 The High Street, Titchfield, Hants.Google Scholar
37.Wilson, BA, Alderman, N, Burgess, H, Emslie, H, Evans, J. Behavioural Assessment of Dysexecutive Syndrome. (Thames Valley Test Co.) Publ. Bury St Edmunds 1996.Google Scholar
38.King, DJ. Neuroleptics and Schizophrenia. In: King, DJ, editor. Seminars in Clinical Psychopharmacology. London: Gaskell 1995: 259–327.Google Scholar
39.Hutton, SB, Crawford, TJ, Puri, BKet al.Smooth pursuit and saccadic abnormalities in first-episode schizophrenia. Psychological Medicine 1998; 28:685–692.CrossRefGoogle ScholarPubMed
40.King, DJ, Mills, PJ, Mannion, MF, Green, JF. Smooth pursuit eye movements in chronic schizophrenics and healthy volunteers using a quantitative objective measure for detecting saccadic intrusions. Human Psychopharmacology 1999; 14: 87–94.3.0.CO;2-E>CrossRefGoogle Scholar
41.Blackwood, DH, Young, AH, McQueen, JKet al.Magnetic resonance imaging in schizophrenia: altered brain morphology associated with P300 abnormalities and eye-tracking dysfunction. Biological Psychiatry 1991; 30: 753–769.CrossRefGoogle ScholarPubMed
42.Katansis, J, Lacono, WG. Clinical, neuropsychological and brain structural correlates of smooth pursuit eye tracking performance in chronic schizophrenia. J Abnormal Psychology 1991; 100: 526–534.Google Scholar
43.Ciuffreda, KJ, Alpert, M, Blackstone, T, Fudge, R, Thaler, J. Pursuit eye movements in chronic schizophrenics: relationship between increased saccades and negative symptoms. Ophthalmology, Physiology, Optometries 1994; 14: 79–81.CrossRefGoogle ScholarPubMed
44.Kelly, P, Rennie, C, Gordon, E, Anderson, J, Howson, A, Meares, R. Smooth pursuit eye tracking dysfunction and negative symptoms in schizophrenia. Psychiatry Research 1990;34:89–97.CrossRefGoogle ScholarPubMed
45.Lawrie, SM, Ingle, GT, Santosh, CGet al.Magnetic Resonance imaging and single photon emmission tomography in treatment - responsive and treatment-resistant schizophrenia. Br J Psychiatry 1995; 167: 202–210.CrossRefGoogle Scholar
46.King, DJ, Green, JF. Medication and cognitive functioning in schizophrenia. In: Pantelis, C, Nelson, HE, Barnes, TRE, editors. Schizophrenia: a neuropsychological perspective. Chichester: John Wiley & Sons Ltd, 1996: Chapter 20, 419–445.Google Scholar
47.Sharma, T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 1999; 174: (suppl. 38), 44–51.CrossRefGoogle Scholar
48.Bartfai, A, Levander, SE, Nyback, H, Berggren, B-M, Schalling, D. Smooth pursuit eye tracking, neuropsychological test performance, and computed tomography in schizophrenia. Psychiatry Research 1985; 15: 49–62.CrossRefGoogle ScholarPubMed
49.van den Bosch, RJ, Rozendaal, N, Mol, JMFA. Symptom correlates of eye tracking dysfunction. Biological Psychiatry 1987; 22: 919–921.CrossRefGoogle ScholarPubMed
50.Friedman, L, Kenny, JT, Jesberger, JA, Choy, MM, Meltzer, HY. Relationship between smooth pursuit eye-tracking and cognitive performance in schizophrenia. Biological Psychiatry 1995; 37: 265–272.CrossRefGoogle ScholarPubMed
51.Radant, AD, Claypoole, K, Wingerson, DK, Cowley, DS, Roy-Byrne, PP. Relationship between neuropsychological and oculomotor measures in schizophrenia patients and normal controls. Biological Psychiatry 1997; 42: 797–805.CrossRefGoogle ScholarPubMed
52.Friedman, L, Jesberger, JA, Meltzer, HY. Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. Psychiatry Research 1992; 41: 25–36.CrossRefGoogle ScholarPubMed
53.Levy, DL, Upton, RB, Yasillo, NJ, Peterson, J, Pandey, G, Davis, JM. Psychotropic drug effects on smooth pursuit eye movements: a summary of recent findings, In: Gale, AG, Johnson, F, editors. Theoretical and Applied Aspects of Eye Movement Research. Elsevier Science Publishers B.V. (North Holland), 1994:497–505.Google Scholar